BridgeMD
New treatment option for Alopecia Areata
Official title A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
ClinicalTrials.gov ID: NCT07533006
What this study is testing
What is LY4005130?
LY4005130 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for alopecia areata.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50
You may be able to join if
- Have severe Alopecia Areata (AA) that meets all of the following criteria:
- Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
- The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
- No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
- Agree not to use any AA treatments during the study
You likely can't join if
- Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
- Are currently experiencing other forms of alopecia
- Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires...
- Have received oral JAK Inhibitors in the past
- Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric...
The study team makes the final eligibility decision.
Where it's taking place
- Fremont, California, United States
- Northridge, California, United States
- Santa Clarita, California, United States
- Cutler Bay, Florida, United States
- Boston, Massachusetts, United States
- Troy, Michigan, United States
- Portsmouth, New Hampshire, United States
- San Antonio, Texas, United States
- South Jordan, Utah, United States
- Kelowna, Canada
- Newmarket, Canada
- Ottawa, Canada
- Verdun, Canada
- Beijing, China
- Shanghai, China
- Tianjin, China
- Rotterdam, Netherlands
- Gdansk, Poland
- Krakow, Poland
- Ostrowiec Świętokrzyski, Poland
+ 7 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fremont, California, United States; Northridge, California, United States; Santa Clarita, California, United States; Cutler Bay, Florida, United States; Boston, Massachusetts, United States; Troy, Michigan, United States and 21 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.